F-Prime Capital — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Antlia Bioscience develops long-acting therapeutics aimed at treating chronic cardiometabolic diseases.
BiotechEncinitas, US
Brian Laurence Johnson(Executive Officer, Director)Ankit Mahadevia(Executive Officer, Director)
BoardBen Auspitz(Director)Carlos Garcia Echeverria(Director)
Board seatMartin TaylorNihal Sinha· per SEC Form D · $20M raise · filed Jun 2026
Notabene provides compliance and regulatory technology for crypto businesses and financial institutions, helping them meet regulatory requirements like the FATF Crypto Travel Rule through real-time screening, sanctions checks, and wallet identification.
Crypto & Web3CybersecurityEnterprise SoftwareFintechNew York City, US
Pelle Braendgaard(CEO/ Co-Founder)inAndres Junge(Founder)inAnia Lipinska(Founder)inAlice Nawfal(Founder)in
BoardMatthew Walsh(Director)Peter Johnson(Director)in
Board seatDavid Jegen· per SEC Form D
Co-investorsDigital Currency GroupParaFi CapitalSignature VenturesWintermuteY CombinatorDRW Venture Capital+4 more
Eigen Innovations applies AI-powered thermal vision to manufacturing, using thermal imaging and machine learning to detect product defects (such as voids, adhesion issues, and material inconsistencies) and continuously monitor equipment and process temperatures.
Advanced ManufacturingAI & Machine LearningHardware
Co-investorsCeltic House Asia PartnersEast Valley VenturesMomenta VenturesAGI HOUSE VENTURESAramco VenturesBenchmark+7 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.